Computational studies on structurally diverse dipeptidyl peptidase IV inhibitors: An approach for new antidiabetic drug development

Medicinal Chemistry Research

Volumn 22, Issue 9, 2013, Pages 4505-4521

  Patel, Bhumika ^a   Ghate, Manjunath ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

Diabetes; Docking; DPP IV; Incretin hormones; Pharmacophore; Virtual screening

Indexed keywords

ALOGLIPTIN; ANTIDIABETIC AGENT; ARGININE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUTAMINE; LINAGLIPTIN; PHENYLALANINE; SAXAGLIPTIN; SITAGLIPTIN; TRICLABENDAZOLE; TYROSINE; VILDAGLIPTIN;

ARTICLE; CATALYST; COMPUTER MODEL; COMPUTER PROGRAM; DATA BASE; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GUNER HENRY SCORE; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; LIGAND BINDING; MATHEMATICAL COMPUTING; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOPHORE; SCORING SYSTEM; STRUCTURE ACTIVITY RELATION; WORKFLOW;

EID: 84881177240     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0455-6     Document Type: Article

References (63)

1. Accelrys Inc., Discovery Studio 2.1(2008) http://www.accelrys.com. Accessed 10 May 2011
2. Akahoshi F et al (2007) Lead optimization of [(S)-c (arylamino)prolyl] thiazolidine focused on c-substituent: indoline compounds as potent DPP-IV inhibitors. Bioorg Med Chem 15:641-655
3. Al-masri IM, Mohammad MK, Taha MO (2008) Discovery of DPP-IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening. ChemMedChem 3:1763-1779
4. Biftu T et al (2007) (3R)-4-[(3R)-3-Amino-4-(2,4,5 trifluorophenyl) butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett 17:49-52
5. Brooks R, Brucolleri RE, Olafson B, States DJ, Swaminathan S (1983) CHARMM: a program for macromolecular energy minimization, and dynamic calculations. J Comput Chem 4:187-217
6. Cheng JD, Dunbrack RL Jr, Valianou M, Rogatko A, Alpaugh RK, Weiner LM (2002) Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 62:4767-4772
7. Chien CH, Huang LH, Chou CY, Chen YS, Han YS, Chang GG et al (2004) One site mutation disrupts dimer formation in human DPP-IV proteins. J Biol Chem 279:52338-52345
8. Deacon CF, Nauck MA, Meier J et al (2000) Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581
9. Eckhardt M, Langkopf E, Himmelsbach F et al (2007) 8-(3-(R)- Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 50:6450-6453
10. Edmondson SD, Wei L, Xu J, Shang J, Xu S et al (2008) Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 18:2409-2413
11. Engel M, Hoffmann T, Wagner L, Wermann M, Heiser U, Keifersauer R, Huber R, Bode W, Demuth H-U, Brandstetter H (2003) The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci USA 100:5063-5068
12. Engel M, Hoffmann T, Manhart S, Heiser U, Chambre S, Huber R, Demuth H-U, Bode W (2006) Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPPIV. J Mol Biol 355:768-783
13. Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, Asakawa T, Takeuchi K, Xu R, Webb DR, Gwaltney SL (2007) Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 50:2297-2300
14. Gao Y-D et al (2007) Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. Bioorg Med Chem Lett 17:3877-3879
15. Guner OF, Henry DR (2000) Pharmacophore perception, development, and use in drug design, IUL Biotechnology Series. International University Line, San Diego
16. Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese JL, Morimoto C, Dang NH (2001) In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma karpas 299. Clin Cancer Res 7:2031-2040
17. Hongmao S (2008) Pharmacophore based virtual screening. Curr Med Chem 15:1018-1024
18. Hopsu-Havu VK, Sarimo SR (1967) Purification and characterization of an aminopeptidase hydrolysing glysyl-proline-naphthylamide. Hoppe Seylers Z Physiol Chem 348:1540-1550
19. Hughes JD, Blagg J, Price DA, Bailey S, DeCrescenzo GA, Devraj RV, Ellsworth E et al (2008) Physicochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 18:4872-4875
20. Jiaang W-T, Tsai T-Y, Hsu T, Chen C-T, Cheng J-H, Chiou MC et al (2009) Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 19:1908-1912
21. Jiang Y-K (2010) Molecular docking and 3D-QSAR studies on β-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors. J Mol Model 16:1239-1249
22. Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K, Mizutani S (2002) Prolonged survival and decreased invasive attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res 62:2753-2757
23. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Weber AE et al (2005) (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl]-1 (2,4,5-trifluorophenyl)butan-2 amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141-151
24. Kirchmair J, Markt P, Distinto S, Wolber G, Langer T (2008) Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection - what can we learn from earlier mistakes? J Comput Aided Mol Des 22:213-228
25. Kondo T et al (2007a) Design and synthesis of long-acting inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem 15:2715-2735
26. Kondo T et al (2007b) Design and synthesis of new potent dipeptidyl peptidase IV inhibitors with enhanced ex vivo duration. Bioorg Med Chem 15:2631-2650
27. Kuhn B, Hennig M, Mattei P (2007) Molecular recognition of ligands in dipeptidyl peptidase IV. Curr Top Med Chem 7:609-619
28. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T et al (2005) Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidase 8 and 9. Diabetes 54:2988-2994
29. Leiting B, Pryor KD, Wu JK, Marsilio F, Patel RA et al (2003) Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J 371:525-532
30. Liang GB et al (2007) Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Bioorg Med Chem Lett 17:1903-1907
31. Lu P, Zhu Y, Xia S, Zhu M, Yi W, Cheng J et al (2010) Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors. Eur J Med Chem 45:4953-4962
32. Lubbers T et al (2007) 1,3-Disubstituted 4-aminopiperidines as useful tools in the optimization of the 2 aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 17:2966-2970
33. Meier JJ, Nauck MA, Kranz D et al (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53:654-662
34. Miyamoto Y, Banno Y, Yamashita T, Fujimoto T, Oi S et al (2011) Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125. Bioorg Med Chem 19:172-185
35. Murugesan V, Sethi N, Prabhakar YS, Katti SB (2011) CoMFA and CoMSIA of diverse pyrrolidine analogues as dipeptidyl peptidase IV inhibitors: active site requirements. Mol Divers 15:457-466
36. Nishio Y, Kimura H, Tosaki S, Sugaru E, Sakai M (2010) Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore. Bioorg Med Chem Lett 20:7246-7249
37. Patell VM, Mathur A, Suman A, Devadoss V, Robin F (2008) Heptanoic acid derivatives as dipeptidyl peptidase inhibitors. US Pat. Appl. Publ., US 2008/0020971 A1
38. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth H-U (1998) Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidine. Diabetes 47:1253-1258
39. Pissurlenkar RS, Shaikh MS, Coutinho ES (2007) 3D-QSAR studies of dipeptidyl peptidase IV inhibitors using a docking based alignment. J Mol Model 13:1047-1071
40. Pospisilik JA, Stafford SG, Demuth S-U, McIntosh CH, Pederson RA (2002) Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglyceemic- hyperinsulinemic clamp study. Diabetes 51:2677-2683
41. Price DA, Blagg J, Jones L, Greene N, Wager T (2009) Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert Opin Drug Metab Toxicol 5:921-931
42. Rawlings ND, Tolle DP, Barrett AJ (2004) MEROPS: the peptidase database. Nucleic Acids Res 32:D160-D164
43. Rummey C, Metz G (2007) Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Proteins 66:160-171
44. Rummey C, Nordhoff S, Thiemannc M, Metz G (2006) In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett 16:1405-1409
45. Saqib U, Siddiqi MI (2009) 3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents. SAR QSAR Environ Res 20:519-535
46. Saydah SH, Fradkin J, Cowie CC (2004) Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335-342
47. Sharma J, Yadav D, Paliwal S (2012) Discovery of novel DPP IV inhibitors: application of pharmacophore-based virtual screening. Med Chem Res. doi: 10.1007/s00044-012-0044-8
48. Smellie A, Teig SL, Towbin P (1995) Poling: promoting conformational variation. Comput Chem 16:171-187
49. Taha MO, Qandil AM, Zaki DD, AlDamen MA (2005) Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modelling. Eur J Med Chem 40:701-727
50. Taha MO, Habash M, Al-Hadidi Z, Al-Bakri A, Younis K, Sisan S (2011a) Docking-based comparative intermolecular contacts analysis as new 3D QSAR concept for validating docking studies and in silico screening: NMT and GP inhibitors as case studies. J Chem Inf Model 51:647-669
51. Taha MO, Qandil AM, Al-Haraznah T, Khalaf RA, Zalloum H, Al-Bakri AG (2011b) Discovery of new antifungal leads via pharmacophore modeling and QSAR analysis of fungal N-myristoyl transferase inhibitors followed by in silico screening. Chem Biol Drug Des 78:391-407
52. Theodorakis MJ, Carlson O, Michopoulos S et al (2006) Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab. 290:E550-E559
53. Triballeau N, Acher F, Brabet I, Pin J-P, Bertrand H-O (2005) Virtual screening workflow development guided by the "Receiver Operating Characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 48:2534-2547
54. Venkatachalam CM, Jiang X, Oldfield T, Waldman M (2003) LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graphics Model 21:289-307
55. Verdonk ML, Marcel L, Berdini V, Hartshorn MJ, Mooij WTM, Murray CW, Taylor RD, Watson P (2004) Virtual screening using protein ligand docking: avoiding artificial enrichment. J Chem Inf Comput Sci 44:793-806
56. Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220-224
57. Ward RA, Perkins TDJ, Stafford J (2005) Structure-based virtual screening for low molecular weight chemical starting points for Dipeptidyl peptidase IV inhibitors. J Med Chem 48:6991-6996
58. Wolber G, Langer T (2005) LigandScout: 3-D pharmacophores derived from protein bound ligands and their use as virtual screening filters. J Chem Inf Comput Sci 45:160-169
59. Wolber G, Dornhofer A, Langer T (2006) Efficient overlay of small organic molecules using 3D pharmacophores. J Comput Aided Mol Des 20:773-788
60. Wu S-Y, Lu I-L, Tsai K-C, Chiang Y-K, Jiaang W-T, Wu S-H (2008) A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. Eur J Med Chem 43:1603-1611
61. Wu J-J, Tang H-K, Yeh T-K, Chen C-M, Shy H-S, Chu Y-R et al (2009) Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP 8/9 inhibitor. Biochem Pharmacol 78:203-210
62. Zeng J, Liu G, Tang Y, Jiang H (2007) 3D-QSAR studies on fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA. J Mol Model 13:993-1000
63. Zweing MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561-577